This activity provides practical insights for pathologists and laboratory professionals who are working to improve how they perform HER2 testing in breast cancer and how they are navigating some of the challenges around reporting HER2-low and HER2-ultralow results. Accurately identifying HER2-low and HER2-ultralow status remains a crucial step when determining patient eligibility for FDA-approved therapies like trastuzumab deruxtecan (T-DXd) in the metastatic setting. This activity was developed by interviewing pathology departments across the country and exploring how they are classifying and reporting HER2-low (IHC 1+ or 2+/ISH-negative) and HER2-ultralow (IHC 0 with minimal membrane staining) results in breast cancer.
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Explain the clinical significance of detecting low levels of HER2 expression in advanced breast cancer
- Design laboratory workflows to achieve effective reporting and communication for HER2-low and HER2-ultralow results
Faculty
Joseph Kim, MD, MPH, MBA, FACHE, CPHQ, FACEHP
President, Q Synthesis LLC
Faculty Disclosures
Dr. Kim has no financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must participate in the course. CME certificates will be provided online.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.